GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shandong Weigao Group Medical Polymer Co Ltd (HKSE:01066) » Definitions » ROC %

Shandong Weigao Group Medical Polymer Co (HKSE:01066) ROC % : 10.88% (As of Jun. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Shandong Weigao Group Medical Polymer Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Shandong Weigao Group Medical Polymer Co's annualized return on capital (ROC %) for the quarter that ended in Jun. 2023 was 10.88%.

As of today (2024-04-27), Shandong Weigao Group Medical Polymer Co's WACC % is 7.02%. Shandong Weigao Group Medical Polymer Co's ROC % is 9.22% (calculated using TTM income statement data). Shandong Weigao Group Medical Polymer Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Shandong Weigao Group Medical Polymer Co ROC % Historical Data

The historical data trend for Shandong Weigao Group Medical Polymer Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Weigao Group Medical Polymer Co ROC % Chart

Shandong Weigao Group Medical Polymer Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.33 12.16 14.34 12.59 9.18

Shandong Weigao Group Medical Polymer Co Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.34 13.91 11.55 10.88 7.62

Shandong Weigao Group Medical Polymer Co ROC % Calculation

Shandong Weigao Group Medical Polymer Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=3423.162 * ( 1 - 12.79% )/( (23612.792 + 23793.153)/ 2 )
=2985.3395802/23702.9725
=12.59 %

where

Invested Capital(A: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37441.466 - 5094.126 - ( 8734.548 - max(0, 6339.969 - 19909.617+8734.548))
=23612.792

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37300.884 - 5147.852 - ( 8359.879 - max(0, 6706.048 - 20421.92+8359.879))
=23793.153

Shandong Weigao Group Medical Polymer Co's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=3040.788 * ( 1 - 15.34% )/( (23793.153 + 23523.352)/ 2 )
=2574.3311208/23658.2525
=10.88 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37300.884 - 5147.852 - ( 8359.879 - max(0, 6706.048 - 20421.92+8359.879))
=23793.153

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37118.239 - 5876.859 - ( 7718.028 - max(0, 7222.703 - 20509.844+7718.028))
=23523.352

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Weigao Group Medical Polymer Co  (HKSE:01066) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Shandong Weigao Group Medical Polymer Co's WACC % is 7.02%. Shandong Weigao Group Medical Polymer Co's ROC % is 9.22% (calculated using TTM income statement data). Shandong Weigao Group Medical Polymer Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Shandong Weigao Group Medical Polymer Co ROC % Related Terms

Thank you for viewing the detailed overview of Shandong Weigao Group Medical Polymer Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Weigao Group Medical Polymer Co (HKSE:01066) Business Description

Traded in Other Exchanges
Address
No.1, Weigao Road, Torch Hi-tech Science Park, Shandong Province, Weihai, CHN
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.

Shandong Weigao Group Medical Polymer Co (HKSE:01066) Headlines

No Headlines